CLINICA 100 TOP 10: Danaher
This article was originally published in Clinica
Executive Summary
Edging its way into the Top 10 for the first time is Danaher. The company moved up one position to No 10 in our Clinica 100 league table*. It continues to be No 2 in the IVD list, behind Roche. Danaher was involved in one of 2015’s mega-mergers, making its biggest buy ever with a $13.8bn deal for filtration technology specialist Pall. The companies serve not only the life sciences market (Danaher more so than Pall) but also other non-healthcare related industries (Pall more so than Danaher). With the acquisition of Pall, the bulked up Danaher plans to split into two publicly listed companies – the concern that will retain the Danaher name will encompass Danaher’s life sciences, diagnostics and dental segments and the other concern will consists of the water quality and product identification platforms and most of the acquired Pall businesses.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.